加拿大静脉注射达巴万星的实际使用经验;CLEAR(加拿大抗菌药物实际使用领导力)登记的结果。

IF 3.7 3区 医学 Q2 INFECTIOUS DISEASES Journal of global antimicrobial resistance Pub Date : 2024-06-20 DOI:10.1016/j.jgar.2024.06.002
George Zhanel , Michael Silverman , Janhavi Malhotra , Melanie Baxter , Reza Rahimi , Neal Irfan , Gabriel Girouard , Rita Dhami , Melissa Kucey , Vida Stankus , Kristin Schmidt , Sébastien Poulin , William Connors , Carlo Tascini , Andrew Walkty , James Karlowsky
{"title":"加拿大静脉注射达巴万星的实际使用经验;CLEAR(加拿大抗菌药物实际使用领导力)登记的结果。","authors":"George Zhanel ,&nbsp;Michael Silverman ,&nbsp;Janhavi Malhotra ,&nbsp;Melanie Baxter ,&nbsp;Reza Rahimi ,&nbsp;Neal Irfan ,&nbsp;Gabriel Girouard ,&nbsp;Rita Dhami ,&nbsp;Melissa Kucey ,&nbsp;Vida Stankus ,&nbsp;Kristin Schmidt ,&nbsp;Sébastien Poulin ,&nbsp;William Connors ,&nbsp;Carlo Tascini ,&nbsp;Andrew Walkty ,&nbsp;James Karlowsky","doi":"10.1016/j.jgar.2024.06.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>We report the use of IV dalbavancin in Canadian patients using data captured by the national CLEAR registry.</p></div><div><h3>Methods</h3><p>The CLEAR registry uses the web-based data management program, REDCap™ (online survey <span>https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=TPMWJX98HL</span><svg><path></path></svg>) to facilitate clinicians entering details associated with their clinical experiences using IV dalbavancin.</p></div><div><h3>Results</h3><p>Data were available for 40 patients. The most common infections treated were acute bacterial skin and skin structure infection (ABSSSI) (62.5% of patients), bone/joint infection (22.5%), bloodstream/vascular infection (7.5%) and endocarditis (5.0%). Dalbavancin was used as directed (75.0%) and empiric therapy (25.0%). MRSA was the most common identified pathogen (70.0%). Dalbavancin was used both in outpatient (e.g., emergency department) (65.0%), and inpatient treatment settings (e.g., hospital ward) (35.0%). Dalbavancin was used due to the convenience of a single dose treatment (77.5%) as well as to facilitate hospital discharge (7.5%). Dalbavancin was primarily used alone (90.0%), and most commonly using a single 1500 mg dose (77.5%). Microbiological success (pathogen eradicated or presumed eradicated) occurred in 88.2% of known cases, while clinical success (cure and/or improvement) occurred in 93.3% of known cases. No adverse events were reported.</p></div><div><h3>Conclusions</h3><p>In Canada, IV dalbavancin is used as both directed and empiric therapy to treat ABSSSI as well as off-label (bone/joint, bacteremia/vascular, endocarditis, device-related) infections. It is used in both outpatient and inpatient settings due primarily to its convenience as a single-dose treatment regimen and to facilitate early hospital discharge. Dalbavancin use is associated with high microbiological and clinical cure rates along with an excellent safety profile.</p></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"38 ","pages":"Pages 154-157"},"PeriodicalIF":3.7000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213716524001140/pdfft?md5=5e8b8877e4041899366ae7302986570c&pid=1-s2.0-S2213716524001140-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry\",\"authors\":\"George Zhanel ,&nbsp;Michael Silverman ,&nbsp;Janhavi Malhotra ,&nbsp;Melanie Baxter ,&nbsp;Reza Rahimi ,&nbsp;Neal Irfan ,&nbsp;Gabriel Girouard ,&nbsp;Rita Dhami ,&nbsp;Melissa Kucey ,&nbsp;Vida Stankus ,&nbsp;Kristin Schmidt ,&nbsp;Sébastien Poulin ,&nbsp;William Connors ,&nbsp;Carlo Tascini ,&nbsp;Andrew Walkty ,&nbsp;James Karlowsky\",\"doi\":\"10.1016/j.jgar.2024.06.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>We report the use of IV dalbavancin in Canadian patients using data captured by the national CLEAR registry.</p></div><div><h3>Methods</h3><p>The CLEAR registry uses the web-based data management program, REDCap™ (online survey <span>https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=TPMWJX98HL</span><svg><path></path></svg>) to facilitate clinicians entering details associated with their clinical experiences using IV dalbavancin.</p></div><div><h3>Results</h3><p>Data were available for 40 patients. The most common infections treated were acute bacterial skin and skin structure infection (ABSSSI) (62.5% of patients), bone/joint infection (22.5%), bloodstream/vascular infection (7.5%) and endocarditis (5.0%). Dalbavancin was used as directed (75.0%) and empiric therapy (25.0%). MRSA was the most common identified pathogen (70.0%). Dalbavancin was used both in outpatient (e.g., emergency department) (65.0%), and inpatient treatment settings (e.g., hospital ward) (35.0%). Dalbavancin was used due to the convenience of a single dose treatment (77.5%) as well as to facilitate hospital discharge (7.5%). Dalbavancin was primarily used alone (90.0%), and most commonly using a single 1500 mg dose (77.5%). Microbiological success (pathogen eradicated or presumed eradicated) occurred in 88.2% of known cases, while clinical success (cure and/or improvement) occurred in 93.3% of known cases. No adverse events were reported.</p></div><div><h3>Conclusions</h3><p>In Canada, IV dalbavancin is used as both directed and empiric therapy to treat ABSSSI as well as off-label (bone/joint, bacteremia/vascular, endocarditis, device-related) infections. It is used in both outpatient and inpatient settings due primarily to its convenience as a single-dose treatment regimen and to facilitate early hospital discharge. Dalbavancin use is associated with high microbiological and clinical cure rates along with an excellent safety profile.</p></div>\",\"PeriodicalId\":15936,\"journal\":{\"name\":\"Journal of global antimicrobial resistance\",\"volume\":\"38 \",\"pages\":\"Pages 154-157\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2213716524001140/pdfft?md5=5e8b8877e4041899366ae7302986570c&pid=1-s2.0-S2213716524001140-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of global antimicrobial resistance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213716524001140\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of global antimicrobial resistance","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213716524001140","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

目的我们利用国家 CLEAR 登记处采集的数据报告了加拿大患者静脉注射达巴万星的使用情况:CLEAR登记处使用基于网络的数据管理程序REDCapTM(在线调查 https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=TPMWJX98HL),方便临床医生输入与他们使用静脉注射达巴万星的临床经验相关的详细信息:结果:共获得 40 名患者的数据。最常见的感染是急性细菌性皮肤和皮肤结构感染(ABSSSI)(62.5%的患者)、骨/关节感染(22.5%)、血流/血管感染(7.5%)和心内膜炎(5.0%)。达巴万星用于指导性治疗(75.0%)和经验性治疗(25.0%)。MRSA 是最常见的病原体(70.0%)。达尔巴万星既用于门诊(如急诊科)(65.0%),也用于住院治疗环境(如病房)(35.0%)。使用达尔巴万星的原因是单剂量治疗方便(77.5%)以及便于出院(7.5%)。达尔巴万星主要用于单药治疗(90.0%),最常用的是单剂量 1500 毫克(77.5%)。88.2%的已知病例取得了微生物学治疗成功(病原体根除或假定根除),93.3%的已知病例取得了临床治疗成功(治愈和/或病情好转)。无不良反应报告:在加拿大,静脉注射达巴万星既可作为指导疗法,也可作为经验疗法,用于治疗ABSSSI以及标签外(骨/关节、菌血症/血管、心内膜炎、设备相关)感染。它既可用于门诊病人,也可用于住院病人,这主要是因为它是一种方便的单剂量治疗方案,便于病人尽早出院。达尔巴万星的微生物学和临床治愈率都很高,而且安全性极佳。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry

Objectives

We report the use of IV dalbavancin in Canadian patients using data captured by the national CLEAR registry.

Methods

The CLEAR registry uses the web-based data management program, REDCap™ (online survey https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=TPMWJX98HL) to facilitate clinicians entering details associated with their clinical experiences using IV dalbavancin.

Results

Data were available for 40 patients. The most common infections treated were acute bacterial skin and skin structure infection (ABSSSI) (62.5% of patients), bone/joint infection (22.5%), bloodstream/vascular infection (7.5%) and endocarditis (5.0%). Dalbavancin was used as directed (75.0%) and empiric therapy (25.0%). MRSA was the most common identified pathogen (70.0%). Dalbavancin was used both in outpatient (e.g., emergency department) (65.0%), and inpatient treatment settings (e.g., hospital ward) (35.0%). Dalbavancin was used due to the convenience of a single dose treatment (77.5%) as well as to facilitate hospital discharge (7.5%). Dalbavancin was primarily used alone (90.0%), and most commonly using a single 1500 mg dose (77.5%). Microbiological success (pathogen eradicated or presumed eradicated) occurred in 88.2% of known cases, while clinical success (cure and/or improvement) occurred in 93.3% of known cases. No adverse events were reported.

Conclusions

In Canada, IV dalbavancin is used as both directed and empiric therapy to treat ABSSSI as well as off-label (bone/joint, bacteremia/vascular, endocarditis, device-related) infections. It is used in both outpatient and inpatient settings due primarily to its convenience as a single-dose treatment regimen and to facilitate early hospital discharge. Dalbavancin use is associated with high microbiological and clinical cure rates along with an excellent safety profile.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of global antimicrobial resistance
Journal of global antimicrobial resistance INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY
CiteScore
8.70
自引率
2.20%
发文量
285
审稿时长
34 weeks
期刊介绍: The Journal of Global Antimicrobial Resistance (JGAR) is a quarterly online journal run by an international Editorial Board that focuses on the global spread of antibiotic-resistant microbes. JGAR is a dedicated journal for all professionals working in research, health care, the environment and animal infection control, aiming to track the resistance threat worldwide and provides a single voice devoted to antimicrobial resistance (AMR). Featuring peer-reviewed and up to date research articles, reviews, short notes and hot topics JGAR covers the key topics related to antibacterial, antiviral, antifungal and antiparasitic resistance.
期刊最新文献
Surveillance and Characteristics of Vancomycin-Resistant Enterococcus Isolates in a Chinese Tertiary Hospital in Shenzhen, 2018 to 2024. Genomic analysis of IMP-8-producing Enterobacter hormaechei with a novel plasmid pK432-IMP. Monte Carlo simulation for dosage optimization of the best available therapy for bloodstream infections secondary to carbapenemase-producing Klebsiella pneumoniae in critically ill patients. Refining the gut colonization Zophobas morio larvae model using an oral administration of multidrug-resistant Escherichia coli. From Forgotten Cure to Modern Medicine: The Resurgence of Bacteriophage Therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1